{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:07:16Z","timestamp":1788908836760,"version":"build-2803163510"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020582","name":"National Institute of Pharmaceutical Education and Research, Raebareli","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.addr.2026.115960","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:54:35Z","timestamp":1788188075000},"page":"115960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Engineering peptide-drug conjugates for targeted cancer therapy: design principle, theranostic imaging, and translational challenges"],"prefix":"10.1016","volume":"239","author":[{"given":"Amit","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awesh K.","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2026.115960_bb0005","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/onc.2014.291","article-title":"Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies","volume":"34","author":"Du","year":"2015","journal-title":"Oncogene"},{"issue":"2018","key":"10.1016\/j.addr.2026.115960_bb0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.addr.2026.115960_bb0015","doi-asserted-by":"crossref","first-page":"1802725","DOI":"10.1002\/adma.201802725","article-title":"Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials","volume":"31","author":"Chen","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115960_bb0020","first-page":"e81","article-title":"Oral toxicity produced by chemotherapy: A systematic review, J. Clin. Exp","author":"Chaveli-Lopez","year":"2014","journal-title":"Dent"},{"key":"10.1016\/j.addr.2026.115960_bb0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ccr.2005.05.024","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"7","author":"Joyce","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2026.115960_bb0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00280-023-04562-3","article-title":"Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities","volume":"92","author":"Rudd","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2026.115960_bb0035","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/1120009X.2023.2300217","article-title":"Mechanisms underlying dose-limiting toxicities of conventional chemotherapeutic agents","volume":"36","author":"Manavi","year":"2024","journal-title":"J. Chemother."},{"key":"10.1016\/j.addr.2026.115960_bb0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eml.2018.02.003","article-title":"Complex mechanics of the heterogeneous extracellular matrix in cancer","volume":"21","author":"Malandrino","year":"2018","journal-title":"Extrem. Mech. Lett."},{"key":"10.1016\/j.addr.2026.115960_bb0045","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/path.1437","article-title":"Functional structure and composition of the extracellular matrix","volume":"200","author":"Bosman","year":"2003","journal-title":"J. Pathol."},{"key":"10.1016\/j.addr.2026.115960_bb0050","doi-asserted-by":"crossref","first-page":"2101428","DOI":"10.1002\/adhm.202101428","article-title":"Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer Therapy","volume":"11","author":"Xu","year":"2022","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2026.115960_bb0055","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/cancers14010238","article-title":"The Functional Role of Extracellular Matrix Proteins in Cancer","volume":"14","author":"Popova","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115960_bb0060","first-page":"167","article-title":"Extracellular Vesicles and Matrix Remodeling Enzymes: The Emerging Roles in Extracellular Matrix Remodeling","volume":"7","author":"Nawaz","year":"2018","journal-title":"Progression of Diseases and Tissue Repair, Cells"},{"key":"10.1016\/j.addr.2026.115960_bb0065","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1002\/jcp.27419","article-title":"Antibody\u2013drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes","volume":"234","author":"Abdollahpour-Alitappeh","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.addr.2026.115960_bb0070","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115960_bb0075","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12935-022-02679-8","article-title":"Potential of antibody\u2013drug conjugates (ADCs) for cancer therapy","volume":"22","author":"Marei","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.addr.2026.115960_bb0080","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1021\/mp5006195","article-title":"Improving the Therapeutic Index in Cancer Therapy by Using Antibody\u2013Drug Conjugates Designed with a Moderately Cytotoxic Drug","volume":"12","author":"Govindan","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115960_bb0085","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14712598.2020.1757067","article-title":"Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy","volume":"20","author":"Goldenberg","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.addr.2026.115960_bb0090","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.3390\/ijms21155510","article-title":"Antibody-Drug Conjugates: The New Frontier of Chemotherapy","volume":"21","author":"Ponziani","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115960_bb0095","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/CM9.0000000000003438","article-title":"Innovative design concepts in tumor-targeting peptide-drug conjugates: Insights into emerging applications","volume":"139","author":"Tan","year":"2026","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.addr.2026.115960_bb0100","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1039\/D0CS00556H","article-title":"Peptides as a platform for targeted therapeutics for cancer: peptide\u2013drug conjugates (PDCs)","volume":"50","author":"Cooper","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115960_bb0105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3390\/bioengineering12050481","article-title":"Peptide\u2013Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress","volume":"12","author":"Jadhav","year":"2025","journal-title":"Bioengineering"},{"key":"10.1016\/j.addr.2026.115960_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247045","article-title":"A \u201cligand-targeting\u201d peptide-drug conjugate: Targeted intracellular drug delivery by VEGF-binding helix-loop-helix peptides via receptor-mediated endocytosis","volume":"16","author":"Michigami","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2026.115960_bb0115","doi-asserted-by":"crossref","first-page":"11469","DOI":"10.1021\/acs.jmedchem.4c00106","article-title":"Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0120","doi-asserted-by":"crossref","first-page":"1328145","DOI":"10.3389\/fimmu.2024.1328145","article-title":"Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115960_bb0125","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/med.22046","article-title":"Engineering peptide drug therapeutics through chemical conjugation and implication in clinics","volume":"44","author":"Rizvi","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.addr.2026.115960_bb0130","first-page":"1180","article-title":"Antibody\u2013Drug Conjugates (ADCs): A Review of Structural Design","volume":"31","author":"Wu","year":"2026","journal-title":"Technological Evolution, and Future Perspectives, Molecules"},{"key":"10.1016\/j.addr.2026.115960_bb0135","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3390\/pharmaceutics18070849","article-title":"Peptide\u2013Drug Conjugates for Targeted Delivery in Hematological Malignancies: From Design Principles to Clinical Application","volume":"18","author":"Zhou","year":"2026","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115960_bb0140","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1039\/D6MD00049E","article-title":"Peptides as multifunctional linchpins in targeted drug conjugates","volume":"17","author":"Li","year":"2026","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0145","article-title":"Development and Mechanistic Evaluation of Cathepsin B-Activatable Peptide-Drug Conjugate PROTACs for Targeted Protein Degradation in Malignant Tumors: Advancing Precision Protein Degradation Therapeutics in Oncology","volume":"22","author":"Zhang","year":"2026","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115960_bb0150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/jcs8010028","article-title":"Recent Advances in pH and Redox Responsive Polymer Nanocomposites for Cancer Therapy","volume":"8","author":"Gaddimath","year":"2024","journal-title":"J. Compos. Sci."},{"key":"10.1016\/j.addr.2026.115960_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/psc.3561","article-title":"Small molecule\u2013 and peptide\u2013drug conjugates addressing integrins: A story of targeted cancer treatment","volume":"30","author":"Paulus","year":"2024","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.addr.2026.115960_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10989-024-10682-y","article-title":"Advances in Homing Peptide Targeted Therapies","volume":"31","author":"Xian","year":"2025","journal-title":"Int. J. Pept. Res. Ther."},{"key":"10.1016\/j.addr.2026.115960_bb0165","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1039\/D0TC05405D","article-title":"Recent progress in functional peptides designed for tumor-targeted imaging and therapy","volume":"9","author":"Wang","year":"2021","journal-title":"J. Mater. Chem. C"},{"key":"10.1016\/j.addr.2026.115960_bb0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/biom16010027","article-title":"From Mechanism to Medicine: Peptide-Based Approaches for Cancer Diagnosis and Therapy","volume":"16","author":"Gouveia","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.addr.2026.115960_bb0175","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/acs.molpharmaceut.8b00924","article-title":"Antibody-Assisted Delivery of a Peptide\u2013Drug Conjugate for Targeted Cancer Therapy","volume":"16","author":"Kim","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115960_bb0180","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00726-015-1928-y","article-title":"Enhancing tumor-specific intracellular delivering efficiency of cell-penetrating peptide by fusion with a peptide targeting to EGFR","volume":"47","author":"Nguyen","year":"2015","journal-title":"Amino Acids"},{"key":"10.1016\/j.addr.2026.115960_bb0185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrd3320","article-title":"G protein-coupled receptors: novel targets for drug discovery in cancer","volume":"10","author":"Lappano","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115960_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/926295","article-title":"Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm","volume":"2013","author":"Barbieri","year":"2013","journal-title":"Int. J. Pept."},{"key":"10.1016\/j.addr.2026.115960_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/pep2.24171","article-title":"Targeting of peptide-binding receptors on cancer cells with peptide-drug conjugates","volume":"112","author":"Worm","year":"2020","journal-title":"Pept. Sci."},{"key":"10.1016\/j.addr.2026.115960_bb0200","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1021\/acsmedchemlett.4c00480","article-title":"A Conjugate of an EGFR-Binding Peptide and Doxorubicin Shows Selective Toxicity to Triple-Negative Breast Cancer Cells","volume":"16","author":"Than","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.addr.2026.115960_bb0205","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1210\/jcem-70-3-661","article-title":"Evaluation of Receptors for Somatostatin in Various Tumors Using Different Analogs*","volume":"70","author":"Srkalovic","year":"1990","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2026.115960_bb0210","doi-asserted-by":"crossref","first-page":"R223","DOI":"10.1530\/JME-14-0011","article-title":"Somatostatin receptor ligands and resistance to treatment in pituitary adenomas","volume":"52","author":"Cuevas-Ramos","year":"2014","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.addr.2026.115960_bb0215","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/s41401-025-01584-w","article-title":"Somatostatin receptor 2 targeting peptide modifications for peptide-drug conjugate treatment of small cell lung cancer","volume":"46","author":"Bo","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.addr.2026.115960_bb0220","doi-asserted-by":"crossref","first-page":"12675","DOI":"10.3390\/ijms241612675","article-title":"NGR-Based Radiopharmaceuticals for Angiogenesis Imaging: A Preclinical Review","volume":"24","author":"Trencs\u00e9nyi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115960_bb0225","doi-asserted-by":"crossref","first-page":"1115495","DOI":"10.3389\/fchem.2023.1115495","article-title":"Peptide-assembled nanoparticles targeting tumor cells and tumor microenvironment for cancer therapy","volume":"11","author":"Zhang","year":"2023","journal-title":"Front. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0230","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jconrel.2004.09.023","article-title":"Targeting tumor angiogenic vasculature using polymer\u2013RGD conjugates","volume":"102","author":"Mitra","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115960_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178632","article-title":"NGR-peptide\u2212drug conjugates with dual targeting properties","volume":"12","author":"Enyedi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2026.115960_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1061186X.2018.1455841","article-title":"RGD peptide-based non-viral gene delivery vectors targeting integrin \u03b1 v \u03b2 3 for cancer therapy","volume":"27","author":"Fu","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2026.115960_bb0245","doi-asserted-by":"crossref","first-page":"17745","DOI":"10.1021\/acsami.7b03682","article-title":"Stapled RGD Peptide Enables Glioma-Targeted Drug Delivery by Overcoming Multiple Barriers","volume":"9","author":"Ruan","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.addr.2026.115960_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118318","article-title":"Peptide-drug conjugates with linker-dependent payload release coordinate dual antitumor efficacy: Intrinsic RGDS-mediated metastasis suppression synergizes with camptothecin cytotoxicity","volume":"189","author":"Cao","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.addr.2026.115960_bb0255","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/polym12091906","article-title":"iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery","volume":"12","author":"Kang","year":"2020","journal-title":"Polymers (Basel)."},{"key":"10.1016\/j.addr.2026.115960_bb0260","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bulcan.2023.08.009","article-title":"Cancer therapy with iRGD as a tumor-penetrating peptide","volume":"110","author":"Thirumalai","year":"2023","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.addr.2026.115960_bb0265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2016.03.008","article-title":"Tumor penetrating peptides for improved drug delivery","volume":"110\u2013111","author":"Ruoslahti","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115960_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0331564","article-title":"A cytotoxic peptide-drug conjugate for tumor-specific delivery of co-injected molecules","volume":"20","author":"Miyamura","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2026.115960_bb0275","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/s41467-020-19540-z","article-title":"Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115960_bb0280","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jconrel.2010.04.011","article-title":"Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting bcr\u2013abl fusion gene in Chronic Myeloid Leukemia cells","volume":"145","author":"Arthanari","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115960_bb0285","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/cncr.11649","article-title":"Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas","volume":"98","author":"Szepeshazi","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2026.115960_bb0290","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.actbio.2021.03.056","article-title":"Tumor cell membrane-based peptide delivery system targeting the tumor microenvironment for cancer immunotherapy and diagnosis","volume":"127","author":"Meng","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2026.115960_bb0295","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.2174\/138920111796117373","article-title":"Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems","volume":"12","author":"Corti","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.addr.2026.115960_bb0300","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ddr.20265","article-title":"Integrin \u03b1 v \u03b2 3 -targeted cancer therapy","volume":"69","author":"Liu","year":"2008","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.addr.2026.115960_bb0305","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1479-5876-10-S1-S1","article-title":"Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery","volume":"10","author":"Li","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.addr.2026.115960_bb0310","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1535-7163.MCT-14-0366","article-title":"Tumor-Penetrating iRGD Peptide Inhibits Metastasis","volume":"14","author":"Sugahara","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2026.115960_bb0315","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1039\/D0BM01755H","article-title":"Cell-penetrating peptides (CPPs): an overview of applications for improving the potential of nanotherapeutics","volume":"9","author":"Desale","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.addr.2026.115960_bb0320","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1208\/s12248-008-9071-2","article-title":"Delivery of Macromolecules Using Arginine-Rich Cell-Penetrating Peptides: Ways to Overcome Endosomal Entrapment","volume":"11","author":"El-Sayed","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115960_bb0325","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/ijms24010829","article-title":"Peptide Drug Conjugates and Their Role in Cancer Therapy","volume":"24","author":"Heh","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115960_bb0330","first-page":"510","article-title":"Exploring the synergistic behavior of paclitaxel and vorinostat upon co-loading in albumin nanoparticles for breast cancer management, Drug Deliv","volume":"14","author":"Abhang","year":"2024","journal-title":"Transl. Res."},{"key":"10.1016\/j.addr.2026.115960_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.111118","article-title":"Functionalized layer-by-layer assembled film with directional 5-fluorouracil release to target colon cancer","volume":"115","author":"Janardhanam","year":"2020","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.addr.2026.115960_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117276","article-title":"Design and synthesis of isatin derivative payloaded peptide-drug conjugate as tubulin inhibitor against colorectal cancer","volume":"285","author":"Sun","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0345","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1038\/s41467-022-31601-z","article-title":"Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy","volume":"13","author":"Hingorani","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115960_bb0350","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3390\/pharmaceutics14071378","article-title":"Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115960_bb0355","series-title":"Multifunct. Theranostic Nanomedicines Cancer","first-page":"147","article-title":"Peptide-drug conjugates in targeted drug delivery to cancer","author":"Debnath","year":"2021"},{"key":"10.1016\/j.addr.2026.115960_bb0360","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1021\/acs.jmedchem.5c00007","article-title":"Recent Advances in Augmenting the Therapeutic Efficacy of Peptide\u2013Drug Conjugates","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0365","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1021\/acsptsci.3c00269","article-title":"Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic","volume":"7","author":"Rizvi","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.addr.2026.115960_bb0370","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1695","article-title":"Brain penetrating peptides and peptide\u2013drug conjugates to overcome the blood\u2013brain barrier and target CNS diseases","volume":"13","author":"Zhou","year":"2021","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115960_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.993182","article-title":"Efficacy and safety of 177Lu-DOTATATE targeted therapy in advanced\/metastatic pulmonary neuroendocrine tumors: A systematic review and meta-analysis","volume":"12","author":"Ma","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2026.115960_bb0380","doi-asserted-by":"crossref","first-page":"26049","DOI":"10.1021\/acs.jmedchem.5c02016","article-title":"18 F-\/ 68 Ga-Labeled Peptide-Based Probes for PET Imaging of ROR1 Expression","volume":"68","author":"Yang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0385","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1021\/acs.jmedchem.0c01530","article-title":"Peptide\u2013Drug Conjugates with Different Linkers for Cancer Therapy","volume":"64","author":"Alas","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0390","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s41061-025-00497-w","article-title":"Recent Advances in Smart Linkage Strategies for Developing Drug Conjugates for Targeted Delivery","volume":"383","author":"Zhang","year":"2025","journal-title":"Top. Curr. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0395","doi-asserted-by":"crossref","first-page":"14740","DOI":"10.1002\/chem.201903127","article-title":"Innovative Linker Strategies for Tumor-Targeted Drug Conjugates","volume":"25","author":"Dal Corso","year":"2019","journal-title":"Chem. \u2013 A Eur. J."},{"key":"10.1016\/j.addr.2026.115960_bb0400","doi-asserted-by":"crossref","first-page":"19871","DOI":"10.1021\/acs.jmedchem.5c01982","article-title":"Recent Advances in Peptide Linkers for Antibody-Drug Conjugates","volume":"68","author":"Li","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0405","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12951-025-03277-2","article-title":"Current progress and remaining challenges of peptide\u2013drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?","volume":"23","author":"Wang","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115960_bb0410","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1021\/acs.bioconjchem.0c00082","article-title":"Recent Trends in In Situ Enzyme-Activatable Prodrugs for Targeted Cancer Therapy","volume":"31","author":"Sun","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0415","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/1061186X.2015.1108324","article-title":"Smart linkers in polymer\u2013drug conjugates for tumor-targeted delivery","volume":"24","author":"Chang","year":"2016","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2026.115960_bb0420","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1021\/bc0499174","article-title":"Synthesis and Characterization of Dextran\u2212Peptide\u2212Methotrexate Conjugates for Tumor Targeting via Mediation by Matrix Metalloproteinase II and Matrix Metalloproteinase IX","volume":"15","author":"Chau","year":"2004","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0425","doi-asserted-by":"crossref","first-page":"8298","DOI":"10.1039\/D5TB00625B","article-title":"Matrix metalloproteinase-triggered self-assembling peptides for biomedical applications","volume":"13","author":"Liu","year":"2025","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2026.115960_bb0430","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1039\/C6TB00688D","article-title":"A stimuli-responsive Janus peptide dendron\u2013drug conjugate as a safe and nanoscale drug delivery vehicle for breast cancer therapy","volume":"4","author":"Li","year":"2016","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2026.115960_bb0435","doi-asserted-by":"crossref","first-page":"2402040","DOI":"10.1002\/smll.202402040","article-title":"Enhanced Tumor Site Accumulation and Therapeutic Efficacy of Extracellular Matrix-Drug Conjugates Targeting Tumor Cells","volume":"20","author":"Chen","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115960_bb0440","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1021\/bc9005283","article-title":"Tumor-Targeting Peptide Conjugated pH-Responsive Micelles as a Potential Drug Carrier for Cancer Therapy","volume":"21","author":"Wu","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0445","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.1021\/acs.jmedchem.3c00382","article-title":"Identification of a pH-Responsive Peptide\u2013Paclitaxel Conjugate as a Novel Drug with Improved Therapeutic Potential","volume":"66","author":"Rizvi","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0450","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bcp.2005.11.003","article-title":"Peptide-bond modified glutathione conjugate analogs modulate GST\u03c0 function in GSH-conjugation, drug sensitivity and JNK signaling","volume":"71","author":"Burg","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.addr.2026.115960_bb0455","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1021\/acs.accounts.5b00406","article-title":"Disulfide-Based Multifunctional Conjugates for Targeted Theranostic Drug Delivery","volume":"48","author":"Lee","year":"2015","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.addr.2026.115960_bb0460","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1021\/acs.bioconjchem.6c00143","article-title":"Synovial Targeting and Redox-Triggered Release: A Dual Strategy in Peptide-Drug Conjugates for Rheumatoid Arthritis","author":"Yang","year":"2026","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0465","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1021\/bc300020f","article-title":"Peptide\u2013Drug Conjugate Linked via a Disulfide Bond for Kidney Targeted Drug Delivery","volume":"23","author":"Geng","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0470","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202300254","article-title":"A Brief Guide to Preparing a Peptide\u2013Drug Conjugate","volume":"24","author":"Bugatti","year":"2023","journal-title":"ChemBioChem"},{"key":"10.1016\/j.addr.2026.115960_bb0475","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/biomedicines9080872","article-title":"Advances and Limitations of Antibody Drug Conjugates for Cancer","volume":"9","author":"Mckertish","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2026.115960_bb0480","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/19420862.2017.1412025","article-title":"Challenges and new frontiers in analytical characterization of antibody-drug conjugates","volume":"10","author":"Wagh","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115960_bb0485","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1021\/bc300520t","article-title":"Activatable Cell Penetrating Peptide-Conjugated Nanoparticles with Enhanced Permeability for Site-Specific Targeting Delivery of Anticancer Drug","volume":"24","author":"Xia","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0490","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40164-022-00347-1","article-title":"Learn from antibody\u2013drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy","volume":"11","author":"Wu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.addr.2026.115960_bb0495","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3389\/fchem.2020.00571","article-title":"Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies","volume":"8","author":"Hoppenz","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/DDDT.S562135","article-title":"Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles, Drug Des","volume":"20","author":"Parang","year":"2026","journal-title":"Devel. Ther."},{"key":"10.1016\/j.addr.2026.115960_bb0505","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s11095-023-03486-0","article-title":"Strategies to improve the physicochemical properties of peptide-based drugs","volume":"40","author":"Lee","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115960_bb0510","doi-asserted-by":"crossref","first-page":"2101633","DOI":"10.1002\/adfm.202101633","article-title":"Protein Engineering Strategies for Improved Pharmacokinetics","volume":"31","author":"Rondon","year":"2021","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.addr.2026.115960_bb0515","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1021\/acs.molpharmaceut.2c00629","article-title":"The Recent Advance of Cell-Penetrating and Tumor-Targeting Peptides as Drug Delivery Systems Based on Tumor Microenvironment","volume":"20","author":"Zhang","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115960_bb0520","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/mol.116.108084","article-title":"Tumor Microenvironment Targeting and Responsive Peptide-Based Nanoformulations for Improved Tumor Therapy","volume":"92","author":"Qin","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.addr.2026.115960_bb0525","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13046-017-0667-1","article-title":"Fate of Antibody-Drug Conjugates in Cancer Cells","volume":"37","author":"Chalouni","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.addr.2026.115960_bb0530","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1016\/j.apsb.2023.02.013","article-title":"Research advances in peptide\u2013drug conjugates","volume":"13","author":"Gong","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2026.115960_bb0535","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1007\/s11095-009-9964-5","article-title":"Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer","volume":"26","author":"Thomas","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115960_bb0540","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody\u2013drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115960_bb0545","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/bc9002019","article-title":"Antibody\u2212Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies","volume":"21","author":"Ducry","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0550","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1021\/acs.jmedchem.3c01835","article-title":"Peptide\u2013Drug Conjugates: An Emerging Direction for the Next Generation of Peptide Therapeutics","volume":"67","author":"Dean","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0555","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jconrel.2013.05.031","article-title":"Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan","volume":"170","author":"Ahn","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115960_bb0560","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1021\/acs.molpharmaceut.8b00177","article-title":"Impact of Payload Hydrophobicity on the Stability of Antibody\u2013Drug Conjugates","volume":"15","author":"Buecheler","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115960_bb0565","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1038\/s41467-020-19498-y","article-title":"Co-administered antibody improves penetration of antibody\u2013dye conjugate into human cancers with implications for antibody\u2013drug conjugates","volume":"11","author":"Lu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115960_bb0570","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1021\/bc300585h","article-title":"Cellular Uptake and Cytotoxicity of Drug\u2013Peptide Conjugates Regulated by Conjugation Site","volume":"24","author":"Zhang","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0575","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3390\/molecules24101855","article-title":"Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety","volume":"24","author":"He","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115960_bb0580","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/med.20225","article-title":"Peptide-mediated targeted drug delivery","volume":"32","author":"Majumdar","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.addr.2026.115960_bb0585","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1208\/s12248-016-9940-z","article-title":"Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy","volume":"18","author":"Cilliers","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115960_bb0590","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4155\/tde.14.111","article-title":"Challenges in the Delivery of Peptide drugs: an Industry Perspective","volume":"6","author":"Lewis","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2026.115960_bb0595","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4161\/mabs.22854","article-title":"Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates","volume":"5","author":"Ritchie","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115960_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107957","article-title":"Blood-brain barrier and blood-brain tumor barrier penetrating peptide-drug conjugate as targeted therapy for the treatment of lung cancer brain metastasis","volume":"196","author":"Zheng","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.addr.2026.115960_bb0605","doi-asserted-by":"crossref","DOI":"10.1002\/psc.70040","article-title":"Peptide-Drug Conjugates: A New Hope for Cancer","volume":"31","author":"Armstrong","year":"2025","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.addr.2026.115960_bb0610","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/1078-0432.CCR-13-0541","article-title":"Trastuzumab Emtansine: A Novel Antibody\u2013Drug Conjugate for HER2-Positive Breast Cancer","volume":"20","author":"Krop","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2026.115960_bb0615","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/17425247.2019.1614911","article-title":"Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors","volume":"16","author":"Jafari","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115960_bb0620","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.actbio.2020.11.008","article-title":"Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment","volume":"119","author":"Zhu","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2026.115960_bb0625","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jconrel.2020.01.003","article-title":"Self-assembling and self-formulating prodrug hydrogelator extends survival in a glioblastoma resection and recurrence model","volume":"319","author":"Schiapparelli","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115960_bb0630","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1016\/j.biomaterials.2012.06.003","article-title":"Controlled release of dexamethasone from peptide nanofiber gels to modulate inflammatory response","volume":"33","author":"Webber","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115960_bb0635","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1021\/acsami.5b04517","article-title":"Activable Cell-Penetrating Peptide Conjugated Prodrug for Tumor Targeted Drug Delivery","volume":"7","author":"Cheng","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.addr.2026.115960_bb0640","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-022-01274-8","article-title":"DTX-P7, a peptide\u2013drug conjugate, is highly effective for non-small cell lung cancer","volume":"15","author":"Jiang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2026.115960_bb0645","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1021\/acs.bioconjchem.8b00208","article-title":"Design and Development of Polysaccharide-Doxorubicin-Peptide Bioconjugates for Dual Synergistic Effects of Integrin-Targeted and Cell-Penetrating Peptides for Cancer Chemotherapy","volume":"29","author":"Mansur","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0650","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s11095-019-2688-2","article-title":"Transferrin Receptor Targeted Cellular Delivery of Doxorubicin Via a Reduction-Responsive Peptide-Drug Conjugate","volume":"36","author":"Li","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115960_bb0655","doi-asserted-by":"crossref","DOI":"10.1002\/psc.3602","article-title":"Peptide-drug conjugate designated for targeted delivery to HER2-expressing cancer cells","volume":"30","author":"Sharma","year":"2024","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.addr.2026.115960_bb0660","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.tips.2021.07.001","article-title":"Peptide\u2013drug conjugate-based novel molecular drug delivery system in cancer","volume":"42","author":"Zhu","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2026.115960_bb0665","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1016\/j.biomaterials.2011.04.070","article-title":"Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts","volume":"32","author":"Zhang","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115960_bb0670","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2016.05.015","article-title":"Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer","volume":"99","author":"Yeh","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115960_bb0675","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.dmpk.2018.11.001","article-title":"Pharmacokinetics of protein and peptide conjugates","volume":"34","author":"Bumbaca","year":"2019","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.addr.2026.115960_bb0680","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/nano11030746","article-title":"Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms","volume":"11","author":"Sun","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.addr.2026.115960_bb0685","doi-asserted-by":"crossref","first-page":"2500150","DOI":"10.1002\/anbr.202500150","article-title":"Peptide\/Antibody\u2013Drug Conjugates for Therapeutic Applications in Inflammatory Disease","volume":"5","author":"Jang","year":"2025","journal-title":"Adv. NanoBiomed Res."},{"key":"10.1016\/j.addr.2026.115960_bb0690","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1021\/acs.nanolett.9b00770","article-title":"Peptide\u2013Drug Conjugate-Based Nanocombination Actualizes Breast Cancer Treatment by Maytansinoid and Photothermia with the Assistance of Fluorescent and Photoacoustic Images","volume":"19","author":"Sun","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2026.115960_bb0695","doi-asserted-by":"crossref","first-page":"12577","DOI":"10.1021\/acsnano.6c01282","article-title":"Triple-Targeted Peptide\u2013Photosensitizer\u2013Drug Conjugate Enables NIR-II Imaging-Guided Multimodal Therapy Against Osteosarcoma","volume":"20","author":"He","year":"2026","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115960_bb0700","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1039\/C0MD00111B","article-title":"Strategies to prolong the plasma residence time of peptidedrugs","volume":"1","author":"Pollaro","year":"2010","journal-title":"Medchemcomm"},{"key":"10.1016\/j.addr.2026.115960_bb0705","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12951-018-0362-1","article-title":"Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells","volume":"16","author":"Kalimuthu","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115960_bb0710","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/adhm.201300601","article-title":"Peptide Dendrimer\u2013Doxorubicin Conjugate-Based Nanoparticles as an Enzyme-Responsive Drug Delivery System for Cancer Therapy","volume":"3","author":"Zhang","year":"2014","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2026.115960_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113430","article-title":"Tumor vasculature-targeting PEGylated peptide-drug conjugate prodrug nanoparticles improve chemotherapy and prevent tumor metastasis","volume":"219","author":"Hao","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115960_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110179","article-title":"Fluorescent RGD-based pro-apoptotic peptide conjugates as mitochondria-targeting probes for enhanced anticancer activities","volume":"127","author":"Rizvi","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.addr.2026.115960_bb0725","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1021\/acschemneuro.2c00442","article-title":"OFP011 Cyclic Peptide as a Multifunctional Agonist for Opioid\/Neuropeptide FF Receptors with Improved Blood\u2013Brain Barrier Penetration","volume":"13","author":"Zhang","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.addr.2026.115960_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114750","article-title":"Characterization of molecular interactions between cannabidiol and human plasma proteins (serum albumin and \u03b3-globulin) by surface plasmon resonance, microcalorimetry, and molecular docking","volume":"214","author":"Liu","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.addr.2026.115960_bb0735","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/jlcr.3522","article-title":"99m T c-labeled NGR -chlorambucil conjugate, 99m T c- HYNIC - CLB -c(NGR) for targeted chemotherapy and molecular imaging","volume":"60","author":"Vats","year":"2017","journal-title":"J. Label. Compd. Radiopharm."},{"key":"10.1016\/j.addr.2026.115960_bb0740","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.3390\/ijms20184511","article-title":"Mechanism of Action of the Tumor Vessel Targeting Agent NGR-hTNF: Role of Both NGR Peptide and hTNF in Cell Binding and Signaling","volume":"20","author":"Valentinis","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115960_bb0745","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ygyno.2014.03.576","article-title":"Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO G)","volume":"133","author":"Emons","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.addr.2026.115960_bb0750","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/bjc.2016.72","article-title":"Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours","volume":"114","author":"Mahalingam","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2026.115960_bb0755","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","article-title":"ANG1005, a Brain-Penetrating Peptide\u2013Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases","volume":"26","author":"Kumthekar","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2026.115960_bb0760","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz244.026","article-title":"Pharmacokinetic (PK) assessment of BT1718: A phase I\/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours","volume":"30","author":"Cook","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2026.115960_bb0765","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202517019","article-title":"Emerging Biomaterials Blocking PD-1\/PD-L1 Pathway for Cancer Therapy","volume":"38","author":"Zhu","year":"2026","journal-title":"Adv. Mater."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:24:46Z","timestamp":1788906286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26001948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":153,"alternative-id":["S0169409X26001948"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115960","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering peptide-drug conjugates for targeted cancer therapy: design principle, theranostic imaging, and translational challenges","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115960"}}